ReviewFrontiers in immunology2022
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06759922 (Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Systematic Review and Meta-Analyses of Aminopeptidases as Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2023Pooled it
- Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection.Nature communications · 2026Article
- PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4-Targeted Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The role of DPP4 in viral infections: from receptor biology to antiviral target.Archives of virology · 2026Review
- Pharmacologic DPP-4 inhibition promotes CD8bioRxiv : the preprint server for biology · 2026Article
- Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
- DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs.Frontiers in cell and developmental biology · 2026Article
- Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence.Frontiers in immunology · 2026Article
- Restoring adenosine balance in axial spondyloarthritis: a stage-specific framework for immune and structural modulation.Frontiers in immunology · 2026Review
- Dual-source DPP4 drives intestinal fibrosis in Crohn's disease: synergistic therapeutic targeting of host and microbiota pathways.Gut microbes · 2025Article
- Comparison of Oral Antidiabetic Medications and Insulin Therapy for Glucocorticoid-Induced Hyperglycemia in Patients with Autoimmune Diseases.Journal of clinical medicine · 2025Article
- Association ofInternational journal of molecular sciences · 2025Article
- Identification and Verification of Immune Metabolism-Related Biomarkers and Immune Infiltration Landscape for Pediatric Opsoclonus Myoclonus Ataxia Syndrome in Neuroblastoma.CNS neuroscience & therapeutics · 2025Article
- Enrichment of Low-Abundance and Low-Molecular-Weight Proteins in Human Milk Using Mass Spectrometry-Based Proteomics.ACS omega · 2025Article
- Intestinal alkaline phosphatase is a receptor for cholesterol-lowering pentapeptide IIAEK and regulates cholesterol homeostasis in mice.Scientific reports · 2025Article
- Article
- Review
- Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments.Pharmacological reviews · 2025Review
- Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis.Arthritis research & therapy · 2025Article
- Chromium and formoterol therapy for obesity-induced asthma in rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dipeptidyl-peptidase IV (DPP4), originally identified as an aminopeptidase in 1960s, is an ubiquitously expressed protease presented as either a membrane-bound or soluble form. DPP4 cleaves dipeptide off from the N-terminal of its substrates, altering the bioactivity of its substrates. Subsequent studies reveal that DPP4 is also involved in various cellular processes by directly binding to a number of ligands, including adenosine deaminase, CD45, fibronectin, plasminogen, and caveolin-1. In recent years, many novel functions of DPP4, such as promoting fibrosis and mediating virus entry, have been discovered. Due to its implication in fibrotic response and immunoregulation, increasing studies are focusing on the potential role of DPP4 in inflammatory disorders. As a moonlighting protein, DPP4 possesses multiple functions in different types of cells, including both enzymatic and non-enzymatic functions. However, most of the review articles on the role of DPP4 in autoimmune disease were focused on the association between DPP4 enzymatic inhibitors and the risk of autoimmune disease. An updated comprehensive summary of DPP4's immunoregulatory actions including both enzymatic dependent and independent functions is needed. In this article, we will review the recent advances of DPP4 in immune regulation and autoimmune rheumatic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.